Verastem Reports Phase 2 Long-Term Follow-Up Data For Duvelisib - Quick Facts

(RTTNews) - Verastem, Inc. (VSTM) reported long-term follow-up data from the DYNAMO study, which met its primary endpoint of Overall Response Rate at the final analysis. DYNAMO is a Phase 2 clinical study evaluating duvelisib, the company's investigational oral monotherapy, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with indolent non-Hodgkin lymphoma whose disease is refractory to both rituximab and chemotherapy or radioimmunotherapy. With 18 months of follow-up, the data continues to be consistent with the primary analysis.

The company said the safety profile of duvelisib monotherapy remains consistent with what has been previously reported in indolent non-Hodgkin lymphoma and other advanced hematologic malignancies.